ReviewChemical science2019
Activatable molecular agents for cancer theranostics.
Review in Chemical science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed.
- Synergistic Effects of Laser-synthesized Silver Nanoparticles and Photosensitizers for enhanced Antibacterial and Anticancer activity.Scientific reports · 2026Article
- Gas-mediated reinforcement of cancer therapies: emerging strategies and future perspectives.Chemical science · 2025Review
- Activatable Photosensitizers: From Fundamental Principles to Advanced Designs.Angewandte Chemie (International ed. in English) · 2025Review
- Circulating Tumor Cells in Cancer Diagnosis, Therapy, and Theranostics Applications: An Overview of Emerging Materials and Technologies.Current pharmaceutical design · 2025Review
- An Overview of the Anticancer Potential of Silver Nanostructures against Cervical Cancer.Pharmaceutical nanotechnology · 2025Review
- The role of manganese-based MRI contrast agents for cancer theranostics: Where do we stand in 2025?Theranostics · 2025Review
- A highly fluorescent and readily accessible all-organic photosensitizer model for advancing image-guided cancer PDT.Journal of materials chemistry. B · 2024Article
- Reactivity-Tunable Fluorescent Platform for Selective and Biocompatible Modification of Cysteine or Lysine.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Harnessing nanotechnology for cancer treatment.Frontiers in bioengineering and biotechnology · 2024Review
- Illumination of Hydroxyl Radical in Kidney Injury and High-Throughput Screening of Natural Protectants Using a Fluorescent/Photoacoustic Probe.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2023Article
- Styrylpyridinium Derivatives for Fluorescent Cell Imaging.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Ligand engineering of AuChemical science · 2023Article
- Fluorescent Probes as a Tool in Diagnostic and Drug Delivery Systems.Pharmaceuticals (Basel, Switzerland) · 2023Review
- The Role of Silver Nanoparticles in the Diagnosis and Treatment of Cancer: Are There Any Perspectives for the Future?Life (Basel, Switzerland) · 2023Review
- Single-atom engineering of hemicyanine and its amphiphilic derivative for optimized near infrared phototheranostics.Chemical science · 2023Article
- ROS-responsive ADPH nanoparticles for image-guided surgery.Frontiers in chemistry · 2023Article
- Development of Geometry-Controlled All-Orthogonal BODIPY Trimers for Photodynamic Therapy and Phototheragnosis.Organic letters · 2022Article
- Recent advances in noble metal complex based photodynamic therapy.Chemical science · 2022Review
- Local detection of pH-induced disaggregation of biocompatible micelles by fluorescence switch ON.Chemical science · 2022Article
- Functionalized Nanomaterials as Tailored Theranostic Agents in Brain Imaging.Nanomaterials (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Theranostics that integrates diagnosis and treatment modalities has attracted great attention due to its abilities of personalized therapy and real-time monitoring of therapeutic outcome. Such a theranostic paradigm requires agents to simultaneously possess the capabilities of targeting, imaging, and treatment. Activatable molecular agents (AMAs) are promising for cancer theranostics, as they show a higher signal-to-noise ratio (SNR), real-time detection of cancer-associated biomarkers, lower normal tissue toxicity, and a higher therapeutic effect. This perspective summarizes the recent advancements of AMAs, which include imaging-guided chemotherapy, imaging-guided photodynamic therapy, and imaging-guided photothermal therapy. The molecular design principles, theranostic mechanisms, and biomedical applications of AMAs are described, followed by a discussion of potential challenges of AMAs in cancer theranostics.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.